What The Study Did: The COVID-19 pandemic has disrupted health care delivery in the United State, and researchers in this study examined changes in total U.S. retail pharmacy sales and sales of buprenorphine products with a U.S. Food and Drug Administration-approved indication for treatment of opioid use disorder.
Authors: Thuy D. Nguyen, Ph.D., of the University of Michigan in Ann Arbor, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamainternmed.2020.7497)
Editor's Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
###
Media advisory: The full study is linked to this news release.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2020.7497?guestAccessKey=ef436ecf-e2b4-4df0-adfe-d8a288640c59&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=122120
JAMA Internal Medicine